Bespoke Extracts, Inc.

AI-generated fair value estimate for this company.

Method: 5-year + terminal unlevered FCF DCF with a dilution/going-concern haircut: revenue base $1.42M TTM (+31.8%); revenue growth 25%/20%/15%/12%/10% (years 1-5, decelerating from recent 31.8% TTM growth); net margin improving from -25% (year 1) to -10%/0%/5%/8% (years 2-5) as the cannabis pre-roll business scales toward breakeven; 25% discount rate (penny-stock/going-concern risk); 3% terminal growth; a 50% equity-value haircut for near-certain future dilutive financing given minimal cash and a history of losses; 11.25M shares outstanding.

Reasoning: Bespoke Extracts ('The Joint Company') is a real, revenue-generating cannabis pre-roll manufacturer with genuine recent growth (TTM revenue +31.8%), but it remains unprofitable with a market cap of only about $18K, signaling the market is pricing in heavy near-term dilution risk; a standard DCF overstates value for a penny stock like this unless explicitly haircut for the dilutive equity raises almost certainly needed to fund continued losses, which is why that adjustment is included.